title: Helicobacter pylori infection up-regulates gland mucous cell-type mucins in gastric pyloric mucosa.
abstract: BACKGROUND
  Two types of mucous cell are present in gastric mucosa: surface mucous cells (SMCs) and gland mucous cells (GMCs), which consist of cardiac gland cells, mucous neck cells, and pyloric gland cells. We have previously reported that the patterns of glycosylation of SMC mucins are reversibly altered by Helicobacter pylori infection. In this study, we evaluated the effects of H. pylori infection on the expression of GMC mucins in pyloric gland cells.
  
  
  METHODS
  Gastric biopsy specimens from the antrums of 30 H. pylori-infected patients before and after eradication of H. pylori and 10 normal uninfected volunteers were examined by immunostaining for MUC6 (a core protein of GMC mucins), alpha1,4-N-acetyl-glucosaminyl transferase (alpha4GnT) (the glycosyltransferase which forms GlcNAcalpha1-4Galbeta-R), and GlcNAcalpha1-4Galbeta-R (a GMC mucin-specific glycan).
  
  
  RESULTS
  MUC6, alpha4GnT, and HIK1083-reactive glycan were expressed in the cytoplasm, supranuclear region, and secretory granules in pyloric gland cells, respectively. The immunoreactivity of MUC6 and alpha4GnT, but not of GlcNAcalpha1-4Galbeta-R, in the pyloric gland increased in H. pylori-associated gastritis, and after the eradication of H. pylori, the increased expression of MUC6 and alpha4GnT in the gastric mucosa of H. pylori-infected patients decreased to almost normal levels. This up-regulation was correlated with the degree of inflammation.
  
  
  CONCLUSIONS
  In addition to the synthesis of GMC mucins increasing reversibly, their metabolism or release may also increase reversibly in H. pylori-associated gastritis. The up-regulation of the expression of gastric GMC mucins may be involved in defense against H. pylori infection in the gastric surface mucous gel layer and on the gastric mucosa.
authors: Second Department of Internal Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
authors: Masahiro
authors: M
authors: Matsuzwa
authors: Hiroyoshi
authors: H
authors: Ota
authors: Masayoshi
authors: M
authors: Hayama
authors: Mu Xia
authors: MX
authors: Zhang
authors: Kenji
authors: K
authors: Sano
authors: Takayuki
authors: T
authors: Honda
authors: Ichiro
authors: I
authors: Ueno
authors: Taiji
authors: T
authors: Akamatsu
authors: Jun
authors: J
authors: Nakayama
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001706:Biopsy; D005260:Female; D005753:Gastric Mucosa / Q000378:metabolism* / Q000473:pathology; D016481:Helicobacter Infections / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D016480:Helicobacter pylori; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D055272:Mucin-6; D009077:Mucins / Q000378:metabolism*; D017351:N-Acetylglucosaminyltransferases / Q000378:metabolism; D011706:Pyloric Antrum; D015854:Up-Regulation
chemical_list: D000900:Anti-Bacterial Agents; C524734:MUC6 protein, human; D055272:Mucin-6; D009077:Mucins; D017351:N-Acetylglucosaminyltransferases